论文部分内容阅读
目的:观察HPV-DNA亚型联合子宫颈液基细胞学在子宫颈癌的早期筛选和检查中的临床作用及效果。方法:2010年3月～2011年3月采用HPV-DNA亚型检测联合液基细胞学对276例不同年龄段妇女宫颈分泌物脱落细胞标本进行宫颈癌筛查。结果:宫颈癌检出率为48.2%。单用HPV-DNA检测的阳性率为51.8%,单用子宫颈液基细胞检测的阳性率为53.6%。HPV阳性检出癌前细胞的几率明显高于HPV阴性(P<0.01)。其中低危型HPV 21例,占阳性标本的14.7%;高危HPV 122例,占阳性标本的85.3%。结论:采用HPV-DNA亚型检测联合液基细胞学对宫颈癌筛查能提高宫颈癌筛选准确率。
Objective: To observe the clinical effect and effect of HPV-DNA subtype combined with cervical liquid-based cytology in early screening and examination of cervical cancer. METHODS: From March 2010 to March 2011, HPV-DNA subtype detection combined with liquid-based cytology was used to screen cervical cancer exfoliated cells in 276 women of different ages. Results: The detection rate of cervical cancer was 48.2%. The positive rate of single HPV-DNA test was 51.8%, and the positive rate of cervical liquid-based cells alone was 53.6%. The positive rate of HPV positive detection of precancerous cells was significantly higher than HPV negative (P <0.01). Among them, 21 were low-risk HPV, accounting for 14.7% of positive samples; 122 were high-risk HPVs, accounting for 85.3% of positive samples. Conclusion: HPV-DNA subtype detection combined with liquid-based cytology for cervical cancer screening can improve the screening accuracy of cervical cancer.